atezolizumab + oxaliplatin + leucovorin + 5-fluorouracil

Atezolizumab + oxaliplatin + leucovorin + 5-fluorouracil is a four-drug combination regimen studied as an adjuvant therapy for stage III colon cancer with deficient DNA mismatch repair (dMMR) or microsatellite instability (MSI). **Atezolizumab** is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), blocking its interaction with the PD-1 receptor to promote anti-tumor immune responses. The other agents—**oxaliplatin** (a platinum-based chemotherapeutic that induces DNA crosslinks and apoptosis), **leucovorin** (a folinic acid that enhances 5-fluorouracil efficacy), and **5-fluorouracil** (an antimetabolite inhibiting thymidylate synthase and DNA synthesis)—form the standard FOLFOX chemotherapy backbone. The combination is intended to synergize cytotoxic chemotherapy with immune checkpoint inhibition to improve disease-free survival in high-risk, surgically resected stage III colon cancer patients with dMMR[1][3][5].

Other names

atezolizumab plus FOLFOXatezolizumab + FOLFOXatezolizumab plus oxaliplatin/leucovorin/fluorouracil